Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perioperative nivolumab plus chemotherapy versus chemotherapy plus placebo in resectable non-small cell lung cancer
NL-OMON59651Phase 3Active, not recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Dec 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of nivolumab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Event-Free Survival (EFS). Started Dec 2019; status: active, not recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON59651.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59651.